http://rdf.ncbi.nlm.nih.gov/pubchem/patent/HU-0002669-A2
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 |
| filingDate | 1998-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79b0e202f859a35c09d9ad513aa56327 |
| publicationDate | 2000-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | HU-0002669-A2 |
| titleOfInvention | Diabetes treatment with dioxothiazolidine and sulfonylurea |
| abstract | BACKGROUND OF THE INVENTION The present invention relates to diabetes mellitus, in particular II. a method of treating diabetes mellitus and diabetes mellitus-related conditions in a mammal, comprising administering to a mammal in need of such treatment an insulin sensitizer such as 5- [4- {2- [N-methyl-N- (2-pyridyl) amino] ethoxy} - benzyl] -2,4-thiazolidinedione, (+) - 5- {4 - [(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2- yl) methoxy] benzyl} -2,4-dioxothiazolidine or troglitazone, 5- {4 - [(1-methylcyclohexyl) methoxy] benzyl} -2,4-dioxothiazolidine or ciglitazone, 5- {4- [2- (5-Ethyl-2-pyridyl) ethoxy] benzyl} -2,4-dioxothiazolidine or pioglitazone or 5 - [(2-benzyl-2,3-dihydro-5-benzopyranyl) -methyl] -2,4-dioxothiazolidine or englitazone, and an effective, non-toxic and pharmaceutically acceptable amount of a single insulin secretagogue such as a sulfonylurea such as glibenclamide, glipizide, gliclazide, glimepiride, tolazamide or tolbutamide. HE |
| priorityDate | 1998-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 231.